Evercore ISI Starts BioNTech With In Line Rating, $100 Price Target

BioNTech (BNTX) has an average rating of outperform and price targets ranging from $89.46 to $171.30, according to analysts polled by Capital IQ. Price: 92.49, Change: -0.23, Percent Change: -0.25

MT NewswiresMay 14 07:58 ET

BioNTech Initiated at In-Line by Evercore ISI Group

BioNTech Initiated at In-Line by Evercore ISI Group

Dow JonesMay 14 05:20 ET

BioNTech Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 8.7% Evercore ISI Group → $100 Initiates Coverage On → In-Line 05/08/2024 22.83% HC Wainwright

BenzingaMay 14 05:08 ET

Express News | BioNTech SE : Evercore ISI Initiates Coverage With in Line Rating; Price Target $100

ReutersMay 14 01:50 ET

We Discuss Why BioNTech SE's (NASDAQ:BNTX) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Yahoo FinanceMay 11 08:32 ET

Novavax Hits a 52-week High as Sanofi Deal Prompts J.P. Morgan Upgrade

Seeking AlphaMay 10 11:15 ET